GLP-1 RAs reduce atherosclerotic plaque burden through anti-inflammatory and endothelial-stabilizing effects37, which may explain the 39.3% and 49.2% risk reductions in acute myocardial infarction compared to DPP-4i and sulfonylureas, respectively. Here, GLP1R is linked to myocardial infarction.